Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned phase III trial of inhaled amikacin in patients with cystic fibrosis who have chronic Psuedomonas lung infections (a revised patient population).

Next Previous
X
Search
Trial Profile

Planned phase III trial of inhaled amikacin in patients with cystic fibrosis who have chronic Psuedomonas lung infections (a revised patient population).

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 05 Feb 2015 Status changed from planning to withdrawn prior to enrolment. This trial was planned to replace TR02-109 in a revised patient population, but appears not to have been conducted.
    • 09 May 2012 The US FDA lifts a clinical hold on trials of inhaled amikacin.
    • 09 May 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top